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The changes in phenotype and function that characterize the differentiation of naïve 
T cells to effector and memory states are underscored by large-scale, coordinated, and 
stable changes in gene expression. In turn, these changes are choreographed by the 
interplay between transcription factors and epigenetic regulators that act to restructure 
the genome, ultimately ensuring lineage-appropriate gene expression. Here, we focus 
on the mechanisms that control T cell differentiation, with a particular focus on the role 
of regulatory elements encoded within the genome, known as transcriptional enhancers 
(TEs). We discuss the central role of TEs in regulating T cell differentiation, both in health 
and disease.
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introduction
The first T cell fate decision occurs in the thymus, where CD4+CD8+ (double positive) T cells selec-
tively and stably down-regulate CD4 or CD8 before exiting the thymus as mature, single positive 
(CD4+ or CD8+), naïve T cells. This initial decision dictates the range of possible fate outcomes for 
each lineage of T cells, and hence the role that they play in host immunity; while being able to adopt 
at least six distinct differentiation states, including Th1, Th2, Th17, and Treg fates, each with specific 
phenotypic and functional characteristics, T cells entering the CD4+ T cell pathway contribute to 
pathogen clearance primarily through the secretion of cytokines that coordinate the activity of other 
immune cells [reviewed in Ref. (1)]. For instance, CD4+ T cells that adopt the Th2 phenotype secrete 
IL-4, which elicits maturation of the B cell-mediated antibody response while regulatory T cells 
(Tregs) function to maintain immune homeostasis through the secretion of immunosuppressive 
cytokines, including IL-10 and TGF-β. CD8+ T cells appear to have a much more limited range of 
fate choices, and their predominant function is in the direct killing of infected or transformed cells 
via the secretion of cytotoxic molecules, including perforin and the granzymes [reviewed in Ref. 
(2)]. Despite these differences in the range of lineage decisions that CD4+ and CD8+ T cells can 
make, pathogen-induced differentiation of T cells of either lineage follows the same general course; 
pathogen recognition results in the differentiation of naïve, quiescent T cells to short-lived effector 
cells that have gained the capacity to express the effector molecules required to clear the infection. 
Importantly, differentiation of naïve T cells results in the generation of long-lived memory cells, 
which relative to naïve cells, respond more readily and rapidly to subsequent infections with the same 
pathogen, providing the basis of T cell-mediated immunity (3, 4). It is currently unclear as to whether 
memory cells differentiate directly from naïve cells, or must first become effector cells. While it is 
understood that the phenotypic and functional differences between cell types are underscored by cell 
type-specific transcriptional profiles (5, 6), how these unique profiles arise and are maintained is far 
September 2015 | Volume 6 | Article 4622
Nguyen et al. Transcriptional enhancers in T cell differentiation
Frontiers in Immunology | www.frontiersin.org
from resolved. Here, we focus on the mechanisms that control the 
establishment and maintenance of T cell identity, with a particular 
focus on the role of genomic elements known as transcriptional 
enhancers (TEs). TEs are DNA sequences often occurring tens 
to hundreds of kilobases away from their cognate gene, which 
activate gene transcription by recruitment of transcription factors 
(TFs) to the gene locus. While TEs were discovered more than 
30 years ago (7), they have recently become the focus of renewed 
interest as evidence accumulates that they play central roles in cell 
fate decisions, and as advances in technology enable them to be 
studied more readily.
Molecular Control of Cellular 
Differentiation
Cellular differentiation results from specific and stable changes in 
gene transcription, such that lineage-appropriate genes are herit-
ably up-regulated, while non-lineage genes are silenced. Thus 
differentiation requires both a mechanism to initiate specific 
transcriptional changes, and another to reinforce those changes, 
allowing stability of the new transcriptional program, within and 
between cell divisions. These aspects of differentiation are linked 
by the interplay between TFs and chromatin modifying proteins, 
where specificity relies on the precise binding of TFs to specific 
sequence motifs occurring within gene regulatory regions (gene 
promoters and enhancers). Transcriptional changes are then ena-
bled by transcription factor-mediated recruitment of chromatin, 
modifying proteins to specific regions of the genome. Following 
recruitment, chromatin modifiers catalyze localized and often 
heritable changes to the genome structure, making the DNA 
template more or less permissive for transcription, thus, result-
ing in gene activation or silencing (8). Since the TFs that drive T 
cell differentiation have been the focus of a number of thorough 
and recent reviews (9–12), this article will focus specifically on 
regulated changes to the chromatin structure that guide T cell 
fate, with a particular focus on TEs.
Control of Gene expression by Modulation 
of the Chromatin Structure
Within eukaryotic cells, the negatively charged DNA is wound 
around positively charged histone protein complexes called 
nucleosomes. This arrangement, termed chromatin, enables 
meters of DNA to fit into a nucleus with a diameter measured in 
microns, but also provides an obstacle to transcription since com-
paction of the genome can occlude access of the transcriptional 
machinery to the genes. As such the positioning of nucleosomes 
along the DNA strand must be tightly regulated to ensure that 
lineage-appropriate genes are accessible for transcription. 
Conversely, by regulated compaction of the DNA, inappropriate 
gene expression can be silenced. Indeed, modulation of localized 
genome compaction – achieved through regulated nucleosome 
positioning – is an important means by which cellular fate deci-
sions are controlled (13, 14).
The location of nucleosomes is regulated by modulated depo-
sition and removal of post-translation modifications (PTMs) to 
the solvent-exposed N-termini of histones. These modifications 
can themselves direct the positioning of nucleosomes by altering 
the affinity of the histones for the DNA, or may serve as sub-
strates for chromatin remodeling complexes that deposit, evict, 
and reposition nucleosomes. For instance, histone acetylation, 
which reduces the net positive charge on the nucleosome, and 
therefore the intimacy of the association between the DNA 
and the nucleosome, is thought to destabilize dense chromatin 
structures, making localized regions of the genome more acces-
sible for transcription (15). Further, acetylation of sequential 
nucleosomes – a characteristic of regulatory regions of actively 
transcribed genes  –  results in charge repulsion, exposing the 
intervening DNA for access by the transcriptional machinery. 
Acetylated histones can also serve as substrates for the binding of 
chromatin remodeling complexes, including the ATP-dependent 
BAF (BRG1- or HRBM-associated factors) and pBAF (poly-
bromo-associated BAF) complexes (16, 17), which rearrange 
chromatin to increase DNA accessibility [reviewed in Ref. (18); 
Figure 1A]. In contrast, histone methylation is associated with 
both active and repressed chromatin states, depending on the 
precise residue modified, and the extent of modification (19). For 
example, trimethylation of lysine 27 of histone 3 (H3K27me3), 
deposited by the Polycomb Repressive Complex 2 [PRC2 (20)] 
and removed by histone demethylases KDM6b and UTX (21), 
is associated with repressed gene transcription. Alternatively, 
H3K4me3, deposited by the Trithorax group proteins and 
removed by the Jarid1 histone demethylases, is associated with 
active transcription [reviewed in Ref. (22)]. Furthermore, histone 
methylation apparently conveys effects on transcription solely 
through indirect means, acting as a substrate for nucleosome 
remodeling complexes. As an example, H3K4me3, which is com-
monly deposited at active gene promoters, serves as a substrate 
for binding of the chromodomain-containing remodeler CHD1, 
which appears to establish accessible chromatin structures by 
nucleosome repositioning (21).
Highlighting the role of modulated deposition of histone 
modifications as a factor controlling cellular differentiation, Wei 
et al. showed that the deposition of H3K27me3 and H3K4me3 
at gene promoters was predictive of gene expression patterns 
within naïve and in vitro differentiated effector CD4+ T cells of 
several specifications (including Th1, Th2, and Treg phenotypes) 
(23). Furthermore, they showed that “bivalent” gene promot-
ers (baring both H3K27me3 and H3K4me3) within naïve cells 
often encoded TFs known to be the key for the establishment of 
effector T cell fates, including TBET and GATA3. These bivalent 
domains mostly resolved to either a transcriptionally repressive 
(H3K27me3+ H3K4me3−) or a transcriptionally permissive 
(H3K27me3− H3K4me3+) state following effector differentiation, 
with the precise patterns largely reflecting the particular fate 
decision. For instance, Th1 differentiation was associated with 
the resolution of the Tbx21 locus (encoding the Th1 defining TF 
TBET) to a permissive (H3K4me3+ H3K27−) signature, with a 
largely repressive (H3K4me3+ H3K27−) signature observed at the 
same locus in Th2 cells. Thus, it appears that bivalent domains 
represent switches that regulate fate specification.
Indicating that the mechanisms observed by Wei et  al. also 
guide regulation of gene expression and differentiation in CD8+ T 
cells, and indeed are relevant in vivo, we have recently showed that 
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changes in the transcriptional profiles of CD8+ T cells differentiat-
ing in response to an acute viral infection also correlated with 
changes in the deposition of H3K4me3 and H3K27me3, across 
the stages of differentiation, including memory (6). Moreover, we 
provided evidence for the coordinated regulation of functionally 
related genes via a mechanism dependent on modulated depo-
sition of histone modifications, by showing that each group of 
genes had similar histone modification profiles in naïve cells, and 
similar patterns of change following differentiation. For instance, 
as per the Wei et al. study described above, bivalent gene promot-
ers largely encoded TFs known to be the key for the establishment 
of effector and memory T cell fates, including TBET and EOMES 
(24). However, following differentiation, the repressive modifica-
tion was selectively removed from the vast majority of these genes, 
coincident with their expression. Thus, it appeared that coordi-
nated removal of the repressive modification from bivalent loci is 
a key step in activating genes required to establish T cell effector 
and memory fates. Moreover, similar coordination was evident 
for immune-related genes, such as interferon-γ (Ifng), which 
were characterized by gene promoters that were H3K27me3+ 
H3K4me3− in naïve cells, but H3K27me3− H3K4me3+ in effec-
tor and memory cells. Again, these changes coincided with gene 
activation following differentiation, highlighting the role played 
by histone PTMs in the regulation of cellular differentiation, 
and further suggesting that genes with similar functions are 
coordinately regulated via a mechanism dependent on regulated 
deposition of histone PTMs.
Aside from changes to the structure of the genome that are 
modulated via nucleosome remodeling, the structure of the DNA 
template can by modified by the addition and removal of methyl 
groups to the nucleotides of the genome. While multiple methyla-
tion states exist, the best characterized of these is 5-methyl cytosine, 
which occurs predominantly in the context of CpG dinucleotides, 
and is strongly associated with transcriptional repression (25). 
CpG methylation conveys its effects via stearic hindrance of 
protein–DNA interactions that would otherwise activate tran-
scription (26, 27). Alternatively, methylated CpG residues act as 
substrates for methyl-CpG-binding domain proteins that, in turn, 
recruit histone deacetylases [HDACs (28–30)], and thus there is 
an interplay between CpG methylation-mediated mechanisms of 
transcriptional control and mechanisms dependent on histone 
post-translational modifications (Figure 1B).
enhancer Form and Function
Transcriptional enhancers are DNA sequences located within 
non-coding regions of the genome that positively regulate gene 
transcription through differentiation state-specific binding of 
activating TFs. In turn, TF binding catalyzes events that lead 
to the establishment of transcriptionally permissive chromatin 
FiGURe 1 | examples of transcriptional regulation via modulation of histone modifications. (A) Activation of a repressed chromatin state: repressed 
chromatin is typified by deposition of histone modifications, including H3K27me3 and densely structured chromatin. In this scenario, activation results from 
demethylation of H3K27, modulated by the histone demthylase KDM6b, followed by acetylation of residues including H3K27 by a histone acetyl transferase (HAT). 
Finally, acetylated histones serve as substrates for histone remodeling complexes including BAF and pBAF, which reduce chromatin density, exposing the 
intervening DNA for access by transcription factors and the transcriptional machinery. (B) Repression of an active chromatin state: active chromatin is typified by 
acetylated histones, unmethylated CpG residues, and high chromatin accessibility. In this scenario, CpG methylation is catalyzed by a DNA Methyltransferase 
(DNMT). Methylated CpG residues then serve as a substrate for methyl-binding domain proteins (MBDs), which recruit histone deacetylases (HDACs). Following 
deacetylation, H3K27me3 is deposited by the Polycomb Repressive Complex 2 (PRC2).
FiGURe 2 | Characteristics of active, poised, and repressed 
transcriptional enhancers and their cognate gene promoters. Active 
transcriptional enhancers are bordered by widely spaced nucleosomes, 
baring modifications including H3K4me2 and H3K27Ac, and are bound by 
the histone acetyltransferase p300 and lineage-specific transcription factors. 
Active enhancers give rise to eRNAs, and are associated with promoters 
baring H3K27Ac and H3K4me3. Relative to active enhancers, poised 
enhancers do not give rise to eRNAs, have H3K27me3 in place of H3K27Ac, 
and have reduced chromatin accessibility. Poised enhancers are also bound 
by the Polycomb Repressive Complex 2 (PRC2), and their associated 
enhancers often have a bivalent signature. Finally, repressed enhancers are 
characterized by dense nucleosome assemblages baring H3K27me3, and 
are bound by PRC2.
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environments, achieved through remodeling of the chromatin 
structure (described below). While the majority of studies of 
differentiation-dependent transcription have focused on gene 
promoters, it is clear that many of the regulatory events control-
ling cell fate decisions occur at TEs. Illustrating this point, a 
hallmark study by Heintzman et al. used genome-wide histone 
modification profiling in five human cell lines derived from vari-
ous tissues, finding that the chromatin state of gene promoters 
was largely invariant across cell types. In contrast, the chromatin 
profiles of TEs were highly dynamic, and described much more 
closely the variation in cell type-specific gene expression than did 
the dynamics of gene promoters (31). Further, these findings have 
now been extended to many different primary cell types [(32, 33) 
reviewed in Ref. (34)].
Transcriptional enhancers were classically defined as short 
sequences of DNA that activate or increase transcription from 
gene promoters when studied in isolation, using plasmid-based 
reporter assays. These assays are typically performed using het-
erologous (often viral) promoters, demonstrating that TEs lack 
inherent promoter specificity. Moreover, enhanced transcription 
is observed regardless of the orientation in which the enhancer is 
cloned, and irrespective of the distance between the enhancer and 
promoter, reflecting the fact that, in vivo, TEs can occur hundreds 
of kilobases up or downstream of the genes that they regulate. 
Finally, mutational analysis shows that TE activity is dependent 
on the binding of TFs to motifs within the enhancer (35–37).
With the recent advent of tools, such as ChIP-Seq, which have 
allowed the genome-wide distribution of proteins that interact 
with the genome to be studied, the classic definition of TEs has 
been further refined to show that, in vivo, TEs exist in poised, 
active, and repressed states, with each state characterized by 
unique histone PTM profiles, and unique TF and transcriptional 
co-regulator-binding profiles [reviewed in Ref. (38); Figure 2]. 
For instance, TEs of active genes are characterized by deposition 
of the activating H3K4me2 and H3K27Ac PTMs, while being 
depleted of the repressive H3K27me3 modification, and having 
low nucleosome density. On the other hand, repressed enhancers 
are enriched for H3K27me3, and depleted of activating modi-
fications, and are nucleosome dense (14, 39). Poised enhancers 
represent a state between activation and repression, being defined 
by H3K4me1 and H3K27me3 deposition, increased chromatin 
accessibility relative to repressed enhancers, and binding by 
the p300 histone acetyltransferase, which also identifies active 
enhancers. However, unlike active enhancers, poised enhanc-
ers lack acetylated histones (40–42). Enhancers marked by this 
poised signature are not transcribed, but can be rapidly activated 
following differentiation, and as such, are reminiscent of bivalent 
domains (H3K4me3+ H3K27me3+) at gene promoters (6, 43). 
Moreover, like the genes marked by bivalent promoters, poised 
enhancers appear to regulate genes that enable cell fate specifica-
tion (42). Thus, poised enhancers may represent “differentiation 
switches”, whereby their activation drives lineage commitment, 
while their repression blocks fates associated with the particular 
genes that they regulate. Finally, as with active enhancers, poised 
enhancers are bound by lineage defining TFs, which appear to be 
required to establish the cell state-specific “enhancersomes” [(44) 
described further below].
Methods for Studying Transcriptional 
enhancers
As mentioned above, active TEs are characterized by low nucleo-
some density (“openness”), and physical (looping) interactions 
with their cognate gene promoters, and give rise to small (~500 nt), 
unstable transcripts known as eRNAs (enhancer RNAs). As 
such, as well as profiling the chromatin state using ChIP and 
ChIP-Seq, measurement of these features can be used to identify 
TEs, both at the level of individual gene loci, and globally. For 
instance, nucleosome density has commonly been studied using 
nuclease protection assays, where native chromatin is treated 
with a nuclease, such as DNAse1, and regulatory regions, includ-
ing TEs, are identified by their being hypersensitive to digestion 
because of their low nucleosome density. Indeed, the DNAse 1 
hypersensitivity (HS) assay has been adapted to allow genome-
wide enhancer mapping (45–47). Recently new and less arduous 
techniques have also been developed to assay chromatin acces-
sibility, including ATAC-Seq (Assay of Transposon Accessible 
Chromatin), which measures chromatin openness based on the 
principle that “closed” regions of the genome are refractory to 
transposon insertion (48). Therefore, by assaying transposon 
insertion sites by high-throughput sequencing, openness can be 
assessed on a genome scale.
FiGURe 3 | The chromatin conformation capture (3C) assay. The 3C 
assay is used to measure chromatin loops that define promoter–enhancer 
interactions. Promoter–enhancer interactions are cross-linked, chromatin is 
then digested with a restriction enzyme, and the resulting restriction 
fragments are ligated under dilute conditions to favor the ligation of DNA 
fragments that are in close proximity due to being held together by 
cross-links. The resulting ligation products are then purified, subjected to 
quantitative PCR, or high-throughput sequencing (Hi-C).
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Chromatin looping is measured using the chromatin confor-
mation capture (3C) assay (Figure  3), and various adaptations 
to allow locus-wide and genome-wide measurement using high-
throughput sequencing technologies (for instance, Hi-C) (49, 50). 
3C involves cross-linking the protein–DNA and protein–protein 
interactions that characterize promoter–enhancer interactions. 
Cross-linked DNA is then digested with a restriction enzyme, and 
the resulting restriction fragments are ligated under conditions 
that favor intra rather than inter molecular ligation, thus allow-
ing enhancers to be ligated to the promoters that they regulate 
(51). These ligation events can, then, be measured at individual 
loci by real-time PCR, or genome-wide using high-throughput 
sequencing.
Finally, CAGE-Seq (Cap Analysis Gene Expression) is used 
to selectively assay capped RNAs, including mRNAs and eRNAs, 
by high-throughput sequencing (32, 52). As eRNAs character-
ize active enhancers, this technique can, therefore, be used for 
enhancer detection as well as to determine the dynamics of 
transcription of eRNAs and their cognate gene transcripts.
Regulation of Type 2 Cytokine expression 
by Transcriptional enhancers
CD4+ T cell differentiation has been a particularly useful model 
for the study of cell fate decisions since the growth factors required 
to drive naïve CD4+ T cells to differentiate multiple effector fates 
have been identified, allowing differentiation of each fate to be 
recapitulated in vitro. From the point of view of the role of TEs 
in CD4+ T cell lineage commitment, the Th1/Th2 paradigm has 
been particularly useful. Briefly, the Th1 and Th2 differentiation 
pathways represent alternate and opposing fate decisions since 
engagement of one differentiation program represses the other. 
For instance, the Th2 lineage is defined by expression of the 
cytokine IL-4, and differentiation of this lineage is dependent on 
the TF GATA3, which directly induces Th2 genes, including IL-4, 
while repressing Th1 genes, such as Ifng (encoding interferon-γ) 
and Tbx21 (encoding TBET), both of which drive Th1 develop-
ment. Thus, GATA3 both induces Th2 differentiation, while 
enforcing repression of the Th1 program [reviewed in Ref. (1, 9)].
IL-4 is encoded within the type 2 locus that also encodes 
the Th2 cytokines IL-5 and IL-13 (Figure  4A). Expression of 
these three genes is co-regulated via a mechanism that involves 
chromatin looping such that the three gene promoters are in 
physical interaction (53–56). Interestingly, this interaction is 
preconfigured in naïve CD4+ T cells, despite the fact that naïve 
T cells are not immediately competent for transcription of the 
type 2 gene cluster. Indeed, this arrangement is also present in 
B cells and fibroblasts, both of which are capable of expressing 
IL-4 and IL-13, and thus the looping mechanisms that regulate 
transcription of the type 2 cluster in CD4+ T cells are not cell 
type-specific. Within T cells, the preconfigured state of the type 
2 locus is critically dependent on the STAT6 TF, since in Stat6−/− 
cells, chromatin looping is dramatically reduced (55). The reason 
for this dependence appears to be that STAT6 directly binds 
throughout the type 2 locus, and therefore may be involved in 
mediating looping interactions. Moreover, STAT6 is also required 
for up-regulation of GATA3, which is itself required for type 2 
locus expression (53).
In order to gain transcriptional competence, the locus control 
region (LCR) located within an intron of the Rad50 gene, which 
separates IL-5 from the other genes of the cluster, has to loop onto 
the clustered gene promoters of the type 2 genes, presumably in 
order to deliver a factor that licenses transcription. Recruitment 
of the LCR to the type 2 promoter cluster is likely dependent on 
GATA3, since overexpression of GATA3 within fibroblasts, which 
have a preconfigured promoter cluster, but cannot recruit the 
LCR to activate transcription following stimulation, enables LCR 
recruitment (55). Indeed GATA3 binds the LCR, suggesting that 
GATA3 is involved in mediating looping (53, 55, 56).
Early studies of the type 2 locus found at least 15 regions of 
DNAse1 HS spread throughout the locus in Th2 cells, suggest-
ing that regulatory circuits controlling expression of the type 2 
cytokines were either highly complex, functionally redundant, or 
a combination of both (57–59). The groups of Flavell, Kubo, and 
Ansel have addressed this question directly, through the genera-
tion of mice with deletions of different hypersensitive sites. To 
date, three regions have been shown to be essential for wild-type 
(WT) expression of the type 2 locus in Th2 cells and one region 
within T follicular helper cells because they contain elements that 
positively control gene expression; Tanaka et al. showed that a 
site within the second intron of IL-4 (HS2) is critical for IL-4 
expression since its deletion largely abrogated IL-4 production 
by in  vitro cultured Th2 cells, and largely ablated the (IL-4-
dependent) asthmatic response of HS2-deficient mice in  vivo 
FiGURe 4 | Differentiation-dependent chromatin looping of the type 2 and interferon gamma loci. (A) In naïve CD4+ T cells, the promoters of the genes 
encoding IL-4, IL-5, and IL-13 are clustered together. Following Th2 differentiation, the locus control region (LCR) contained within a 3′ intron of the Rad50 gene 
loops onto the clustered promoters, licensing cytokine expression. DNAse1 hypersensitive sites are shown by arrows, with sites shown to be critical for cytokine 
expression named. (B) In contrast to the type 2 locus, chromatin loops at the murine interferon-gamma (IFNG) locus are acquired as naïve CD4+ T cells differentiate 
to the Th1 fate. Enhancers are shown by purple circles with their coordinates shown relative to the transcription start site (0 kb).
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(56). Moreover, these defects were likely due to the deletion of 
a GATA3 binding site within HS2, because unlike WT cells, 
HS2-deficient CD4+ T cells did not produce IL-4 upon GATA3 
overexpression. Finally, HS2 deletion resulted in reduced levels 
of histone acetylation and H3K4 methylation at various posi-
tions across the type 2 locus in Th2 cells, indicating that GATA3 
binding at HS2 is required to establish a transcriptionally permis-
sive chromatin landscape. Providing a mechanism for GATA3 
dependent chromatin remodeling at the type 2 locus, Hosokawa 
et al. showed that GATA3 is required for recruitment of the his-
tone acetyltransferase p300 to several positions within the type 2 
locus, including HS2, the LCR, and all three cytokine promoters 
(60). The same work showed that within Th2 cells, GATA3 targets 
a HDAC to a TE of Tbx21 (encoding TBET), resulting in gene 
repression. Thus, the same TF associates with both positive and 
negative regulators of chromatin accessibility within the same 
cell lineage, enabling it to both drive Th2 differentiation, and to 
repress Th1 differentiation.
Richard Flavell’s group showed that as per HS2, deletion of 
hypersensitive sites RHS6 and RHS7, which occur within the type 
2 LCR and also serve as sites for GATA3 binding, largely abolished 
IL-4 production, although it is notable that these deletions also 
diminished IL-5 and IL-13 expression, which were unaffected 
following HS2 deletion (56). Moreover, as with HS2, deletion of 
RHS6 resulted in reduced deposition of histone acetylation and 
H3K4me3 at the IL-4, IL-5, and IL-13 promoters under type 
2 conditions, while an increased deposition of the repressive 
H3K27me3 modification was observed, suggesting that GATA3 
binding is required at several regions of the type 2 locus to allow 
establishment of a permissive chromatin signature. The effect of 
RHS7 deletion appears to be through changes to the chromatin 
looping behavior of the type 2 locus since deletion of RHS7 
blocks LCR recruitment to the promoter cluster, indicating that 
recruitment of the LCR may deliver factors that remodel the type 
2 cytokine promoters to facilitate transcription (54). The group 
of Kohwi-Shigematsu demonstrated using RNA interference that 
looping interactions at the type 2 locus are largely mediated by 
the genome organizing protein, SATB1, which binds the type 2 
locus at multiple positions, including within RHS7 (53). Thus, 
taken together, these data indicate that RHS7 positively regulates 
expression of the type 2 cytokines through binding of SATB1, 
which in turn, facilitates the necessary chromatin looping inter-
actions. Finally, Vijayanand et al. showed that while deletion of 
HS V – a HS site occurring downstream of IL-4 – had little or 
no effect on type 2 cytokine expression in Th2 cells, expression 
of both IL-4 and IL-13 was reduced in follicular helper T cells 
(61). Thus it appears that a combination of the complexity of the 
regulatory mechanism, and the need to specify transcription in 
multiple cell lineages may explain the number of type 2 locus 
regulatory regions.
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Transcriptional enhancers Regulate 
Differentiation-Dependent interferon-γ 
expression
In contrast to the type 2 locus, where chromatin loops are largely 
preconfigured, the interferon gamma (Ifng) locus lacks any dem-
onstrated enhancer looping within naïve CD4+ T cells (Figure 4B) 
(62). However, regulation of IFNG expression is similarly complex, 
with 12 TEs identified to date, most of which contain binding sites 
for the Th1 defining TF T-BET (encoded by Tbx21) [reviewed by 
Balasubramani et al. (63)], which is required for IFNG expression 
(64). Indeed Sekimata et  al. demonstrated that the formation of 
chromatin loops within Th1 cells is dependent on T-BET, since in 
T-BET deficient cells, most of the looping interactions that char-
acterize WT Th1 cells are greatly diminished (62). Moreover, they 
provided a likely mechanism: T-BET deficiency reduced binding 
of the insulator factor CTCF at the Ifng promoter and +  66  kb 
enhancer. In turn, CTCF is required for looping at the Ifng locus, 
since knock-down of CTCF diminished looping, but importantly, 
did not reduce T-BET binding. Thus, taken together, these data 
indicated that T-BET likely recruits CTCF to the Ifng locus, enabling 
the chromatin looping interactions that facilitate IFNG expression.
The question of the importance of one of the Ifng TE (−22 kb) 
has been assessed by the generation of a knock-out mouse, the 
result being significantly reduced expression of IFNG in Th1 cells 
as well as in effector CD8+ T cells and natural killer cells (65). 
Moreover, deletion correlated with changes in the histone modi-
fication landscape of the Ifng locus, with reduction in permissive 
H3K4 methylation and H3K12 acetylation modifications in Th1 
cells, relative to the WT. Recruitment of RNA polymerase to the 
Ifng gene promoter was also reduced in −22 deficient Th1 cells, 
indicating that the deletion alters gene expression by directly 
impacting the initiation of gene transcription, fitting with the 
notion that enhancer looping licenses gene transcription.
The question of the functional redundancy of the Ifng regulatory 
regions has also been addressed through transgene studies, whereby 
transgenic mice carrying fragments of the human Ifng locus were 
generated. Using this approach, Thomas Aune’s group have defined 
four regulatory regions that are essential for WT IFNG expression 
in human cells: an element occurring at −30 kb (corresponding to 
the −34 kb enhancer of mice), which is required for WT expression 
in Th1 cells, effector CD8+ T cells and Natural Killer T cells (NKT 
cells), but not in NK cells; a +20 kb enhancer, which is required 
for IFNG expression by memory Th1 and NKT cells, and a −4 kb 
enhancer, which is required for Th1 IFNG expression (66, 67). 
Finally, they defined a −16 kb region that harbors repressive func-
tion since deletion resulted in increased expression of IFNG within 
Th1, Th2, and effector CD8+ T cells. Thus, taken together with the 
data described above, these studies of the Ifng locus support the 
notion that multiple enhancers are required to specify transcription 
within different cell types and between differentiation states.
Regulation of CD8α expression During T Cell 
Development and effector Differentiation
A well defined example of TE mediated regulation within CD8+ T 
cells is provided by the regulation of CD8α itself. Indeed, as CD8α 
is expressed by cell types other than CD8+ T cells, including CD8+ 
dendritic cells and some intestinal intraepithelial lymphocytes 
(IELs), studies of CD8α expression have been particularly 
informative in terms of the role of TEs in cell type-specific regula-
tion. Within conventional T cells, CD8α is up-regulated at the 
double positive (CD4+CD8+; DP) stage of thymic development, 
and subsequently repressed or permanently expressed at the 
expense of CD4 as T cells commit to either the CD4 or CD8 T 
cell lineage, respectively. Expression of CD8α is controlled by five 
TEs (E8I–V), which occur upstream of Cd8α with E8IV occurring 
within an intron of Cd8β [reviewed in Ref. (68)]. The groups of 
Littman and Ellmeier have assessed the role of each of the Cd8α 
enhancers through the generation of knock-out mice and the 
use of transgene reporter assays. For instance, while deletion of 
E8I has no effect on the development of conventional αβ CD8+ 
T cells, it largely blocks the development of αα CD8+ IEL which 
develops extrathymically (69). Therefore, it appears that differ-
ent environmental signals engage different Cd8α enhancers to 
establish CD8α expression. Interestingly however, E8I is required 
for stable CD8α expression following effector differentiation of 
conventional αβ CD8+ T cells (70). These data were surprising in 
light of earlier findings that E8I drives transgene expression in DP, 
CD8 SP, and mature peripheral CD8+ T cells, and suggested that 
another element could compensate for the deletion of E8I. Indeed, 
Ellmeier et al. had previously shown that E8II compensated for 
loss of E8I by generating mice that lacked both enhancer elements, 
since the mice displayed variegated expression of CD8α at the DP 
stage (71). Taken together, studies of the Cd8α locus illustrate that 
multiple TEs are required to allow cell type and differentiation 
state specific transcription, however, unlike the Ifng and type 2 
loci, some degree of functional redundancy also exists.
Providing an explanation for the functional requirement of 
E8I and E8II described above, Billic et al. showed that deletion of 
DNA Methyltransferase 1 (DNMT1) in E8I E8II double-deficient 
mice partially restored CD8α expression, indicating that E8I and 
E8II function in recruiting factors that result in removal of CpG 
methylation (72). Further, while WT DP cells have low levels 
of CpG methylation at a number of regions within E8v, these 
regions are hypermethylated in E8I and E8II (double) deletion 
mice, further arguing that E8I and E8II function to recruit factors 
that demethylate the Cd8α locus. In agreement with this, Harland 
et al. have shown that the CpG methylation status of E8v as well 
as the Cd8α promoter and two intergenic regions is inversely 
correlated with CD8α expression by assaying methylation from 
the DN stage, through DP, SP and mature CD8+ T cells stages 
(73). The latter study also showed that when effector CD8+ T cells 
were differentiated in the presence of IL-4, CD8α expression was 
down-regulated, which coincided with increased CpG methyla-
tion at the regions they assayed. Thus it appears that modulated 
deposition of methyl CpG at multiple sites of the Cd8α locus, 
including the promoter and EV, regulates CD8α expression. 
Moreover, EI and EII are likely to be required for the recruitment 
of factors responsible for demethylation of the locus, which is a 
perquisite for CD8α expression.
Finally, the group of Kioussis have shown that CD8α expres-
sion correlates positively with looping of enhancers I–IV of the 
CD8α locus onto the CD8α gene promoter (E8V was not studied) 
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(74). Moreover, using 3D Fluorescence In  situ Hybridization 
(FISH), they showed that the positioning of the CD8α locus 
within the nucleus is also modulated, with expression coinciding 
with repositioning of the locus, presumably toward regions of 
the nucleus that are dense with RNA polymerase (“transcription 
factories”). Thus, it would be interesting to determine whether 
deletion of specific enhancers, as described above, results in aber-
rant CD8α expression because of a failure to properly position the 
locus within CD8+ T cells.
insights into T Cell enhancer Function 
from whole Genome Studies
The advent of high-throughput sequencing-based technologies 
has allowed the generality of observations made at individual 
gene loci to be tested at the level of the genome. In turn, these 
approaches have provided novel insights into the processes regu-
lating cellular differentiation. For example, Vahedi et al. recently 
asked how the STAT family of TFs regulates Th1/Th2 differentia-
tion by comparing enhancer usage in the two cell types within 
WT and STAT deficient mice (44). STAT TFs are key regulators 
of T cell differentiation, providing a direct link between signaling 
events occurring at the cell membrane which initiate cellular 
differentiation, and the transcriptional changes that result. In 
particular, STAT proteins enable integration of cytokine medi-
ated signaling to shape appropriate T cell differentiation. For 
instance, IL-4 signals received via the IL-4 receptor result in 
STAT6 phosphorylation, homodimerisation, and translocation 
to the nucleus. Once in the nucleus, STAT6 directly binds to the 
genome, regulating transcription of genes, such as GATA3, which 
in turn drive Th2 differentiation. Other examples include IL-2 
signaling via STAT5, which drives Treg differentiation, and IFN-γ 
signaling via STAT1, which drives Th1 differentiation [reviewed 
in Ref. (75)].
While the importance of STAT binding to gene promoters has 
been clear for some time, binding of STATs to enhancer regions 
has recently become recognized as equally essential for T cell line-
age specification and function. Vahedi et al. showed that while 
many enhancers (defined as p300+ H3K4me1+) were shared by 
Th1 and Th2 cells (~13,000), each lineage had a surprisingly large 
number of unique enhancers (~9,000 for Th1 cells and ~7,000 
for Th2 cells), given the close relationship between the cell types. 
The authors further demonstrated that many of the differences in 
the distribution of p300, a marker of lineage-specific enhancers, 
between Th1 and Th2 were explained by the action of STAT fam-
ily TFs: by comparing p300 binding in WT and STAT6−/− mice, 
they showed that ~5,500 p300 sites disappeared from Th2 cells 
in the absence of STAT6, while the enrichment of H3K4me1 at 
those sites was also reduced. Furthermore, STAT4−/− mice had 
over 3,000 p300 peaks absent in Th1 cells relative to the WT. 
Indeed STAT4 binding accounted for nearly double the number 
of p300 peaks accounted for by T-BET – the master regulator of 
Th1 differentiation. Thus, this study highlighted a key role for 
STAT family TFs in establishing cell type specific enhancer usage, 
and in turn, the establishment of the transcriptional programs 
that define Th1 and Th2 cells.
The finding (described earlier) that type 2 effector cytokines 
are co-regulated via shared promoter and enhancer interactions 
raises questions about the generality of that mechanism. Indeed, 
since other immune genes, including those encoding chemokines 
and chemokine receptor also occur as closely spaced, conserved 
gene clusters (76), it is possible that the mechanism described for 
the type 2 locus might be used to co-regulate other immune genes. 
Keji Zhao’s group recently used a technique called chromatin 
interaction analysis by paired-end tag sequencing (ChIA-PET), 
which combines ChIP with 3C to detect looping events that are 
associated with the binding of particular proteins, to detect simi-
lar interactions in human CD4+ T cells (77). In their study, Zhao’s 
group used H3K4me2 as the target for ChIP to enrich interactions 
involving active gene enhancers and promoters. They found that 
transcription of lineage-specific genes is controlled by networks 
of enhancer–promoter and promoter–promoter interactions. 
Specifically, they found that single enhancers could interact with 
multiple promoters that a large number of promoters interact 
with multiple enhancers, and surprisingly, ~3,600 instances of 
promoter–promoter interactions. Importantly, they found that 
genes with promoters that have interacting enhancers were more 
highly transcribed, and the level of transcription scaled with the 
number of enhancers interacting with the promoter. Finally, genes 
linked by promoter–promoter interactions were co-transcribed 
in a tissue-specific manner, indicating that these interactions may 
achieve the coordination of functionally related genes. Moreover, 
these observations were in broad agreement with Li et al., who 
performed ChIA-PET on four varied human cell lines using an 
antibody against RNAPII, and thus are likely to represent a gen-
eral means by which lineage-specific transcriptional programs 
are coordinated (78).
Finally, the studies described above have probed the question 
of the roles and mechanisms of TE-mediated gene regulation dur-
ing normal T cell development; however, it has recently become 
apparent that TEs also have roles to play in disease states. Seumois 
et al. demonstrated that genome-wide enhancer profiling may be 
used to delineate the mechanistic basis of autoimmune disease 
(79). In this study, the authors performed ChIP-Seq for a single 
histone modification (H3K4me2) that marks poised and active 
TEs, comparing asthmatic and healthy patients. They found 
that differences in enhancer usage and the extent of H3K4me2 
enrichment existed within the naïve, Th1 and Th2 CD4+ T cells 
of healthy versus asthmatic patients, but tellingly, the differences 
were greatest within memory Th2 phenotype cells, which is of 
interest because aberrant accumulation of memory Th2 cells 
is an important step in asthma development. Supporting the 
notion that these changes are causative, the asthma-associated 
enhancers discovered by this study mapped to a number of 
regions that regulate asthma associated genes. For instance, 
three regions mapping to the LCR of the type 2 locus showed 
increased enrichment for H3K4me2 in asthma derived Th2 cells, 
relative to the healthy controls. Finally, as far as a mechanism by 
which differential enhancer usage may impact disease progres-
sion, they found that ~40% of the asthma-associated enhancers 
contained binding sites for TFs that are associated with T cell 
differentiation, including GATA3 and TBET. Thus, it appears 
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that differences in enhancer usage impacts expression of genes 
associated with asthma progression by influencing TF binding, 
although the reason that the enhancer profiles of healthy and 
asthmatic patients differed to begin with is yet to be determined. 
Consistent with the observations of Seumois et al., John O’Shea’s 
group has shown that mapping of so-called super-enhancers 
(SEs) within differentiating T cells enabled the delineation of 
disease-associated regulatory networks (80). SEs are defined 
as clusters of conventional TEs that have close spacing, which, 
when active, are enriched for lineage specifying TFs, and the 
transcriptional co-activators p300 and Mediator of RNA poly-
merase II subunit 1 (Med1) [reviewed in Ref. (81)]. Importantly, 
SEs are highly enriched at lineage defining genes. For instance, 
studying Th1, Th2 and Th17 cells, the O’Shea study showed that 
SEs characterized cytokine and cytokine receptor encoding loci, 
as expected for helper T cells, and were enriched for TFs that 
defined each lineage – T-BET within Th1 cells, GATA3 in Th2 
cells, and ROR-γt in Th17 cells. The SEs were also highly enriched 
for STAT family proteins, consistent with the finding that STAT 
proteins are essential for the establishment of the lineage-specific 
“enhancersomes” of Th1 and Th2 cells. Interestingly, a SE at the 
BACH2 locus was active in all three lineages, and BACH2 binding 
sites were highly enriched within the SEs of each cell type. By per-
forming RNA-Seq on BACH2 proficient and sufficient mice, they 
could show that BACH2 represses effector functions associated 
with each T cell lineage. Finally, they showed that SNPs associated 
with autoimmune diseases including rheumatoid arthritis and 
type 1 diabetes, but not SNPs associated with non-autoimmune 
diseases, such as cancer or type 2 diabetes, were enriched within 
SEs relative to conventional enhancers. Thus, consistent with the 
findings of Seumois et  al., lineage specifying TEs appear to be 
hotspots for potentially pathogenic SNPs.
Concluding Remarks
Transcriptional enhancers have key roles to play in the differen-
tiation of T cells, as well as in the development of disease states, 
including autoimmune diseases, indicating that a thorough under-
standing of their biology may lead to opportunities to modulate 
immunity for benefit as well as to understand the mechanistic basis 
of immune pathologies. Much of our knowledge of the role of TEs 
as regulators of T cell differentiation has come from the genera-
tion of mice baring specific enhancer deletions. For instance, this 
strategy has been critical to our understanding of the regulation 
of the type 2 locus, which serves as one of the most detailed para-
digms of enhancer-mediated gene regulation in any cell type. With 
recent advances in our ability to rapidly generate mice with precise 
genetic lesions, including the CRISPR/Cas9 technology [reviewed 
in Ref. (82)], these types of studies should progress at an increasing 
rate. Moreover, as technological advances are starting to enable 
transcriptional regulation to be probed within single cells, many 
questions that were previously impossible to address are becoming 
tractable. In particular, studies of rare populations such as naïve 
precursors and antigen-specific memory T cells can now begin 
to be asked. These include questions about the role that TEs play 
in the establishment and maintenance of immune memory, and 
memory recall capacity, and whether or not differential enhancer 
engagement might explain differences between highly efficacious 
vaccines, and those that confer weak or waning immunity.
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